Aspirate from human stented saphenous vein grafts induces epicardial coronary vasoconstriction and impairs perfusion and left ventricular function in rat bioassay hearts with pharmacologically induced endothelial dysfunction

Physiological Reports

Volumn 4, Issue 15, 2016, Pages

  Lieder, Helmut R ^a   Baars, Theodor ^a   Kahlert, Philipp ^a   Kleinbongard, Petra ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Coronary artery disease; coronary microcirculation; myocardial ischemia; saphenous vein graft; vasoconstriction

Indexed keywords

BIOLOGICAL FACTOR; SEROTONIN;

ANIMAL; BLOOD; CORONARY ARTERY BYPASS GRAFT; CORONARY BLOOD VESSEL; HEART VENTRICLE; HUMAN; LEWIS RAT; MALE; PATHOPHYSIOLOGY; RAT; SAPHENOUS VEIN; STENT; TRANSPLANTATION; VASOCONSTRICTION;

ANIMALS; BIOLOGICAL FACTORS; CORONARY ARTERY BYPASS; CORONARY VESSELS; HEART VENTRICLES; HUMANS; MALE; RATS; RATS, INBRED LEW; SAPHENOUS VEIN; SEROTONIN; STENTS; VASOCONSTRICTION;

EID: 84982175184     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12874     Document Type: Article

References (39)

1. ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. 2006. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 113:e166–e286.
2. Angiolillo, D. J., J. A. Jakubowski, J. L. Ferreiro, A. Tello-Montoliu, F. Rollini, F. Franchi, et al. 2014. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J. Am. Coll. Cardiol. 64:1005–1014.
3. Baars, T., P. Kleinbongard, D. Boese, T. Konorza, S. Moehlenkamp, J. Hippler, et al. 2012. Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential. Basic Res. Cardiol. 107:303.
4. Bax, W. A., G. J. Renzenbrink, van der Linden E. A., F. J. Zijlstra, van Heuven-Nolsen D., D. Fekkes, et al. 1994. Low-dose aspirin inhibits platelet-induced contraction of the human isolated coronary artery. A role for additional 5-hydroxytryptamine receptor antagonism against coronary vasospasm? Circulation 89:623–629.
5. Bell, R. M., M. M. Mocanu, and D. M. Yellon. 2011. Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J. Mol. Cell. Cardiol. 50:940–950.
6. Bove, A. A., and J. D. Dewey. 1983. Effects of serotonin and histamine on proximal and distal coronary vasculature in dogs: comparison with alpha-adrenergic stimulation. Am. J. Cardiol. 52:1333–1339.
7. Brennan, J. M., W. Al-Hejily, D. Dai, R. E. Shaw, M. Trilesskaya, S. V. Rao, et al. 2015. Three-year outcomes associated with embolic protection in saphenous vein graft intervention: results in 49 325 senior patients in the Medicare-linked National Cardiovascular Data Registry CathPCI Registry. Circ. Cardiovasc. Interv. 8:e001403.
8. Chester, A. H., G. R. Martin, M. Bodelsson, B. Arneklo-Nobin, S. Tadjkarimi, K. Tornebrandt, et al. 1990. 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovasc. Res. 24:932–937.
9. Chilian, W. M., K. C. Dellsperger, S. M. Layne, C. L. Eastham, M. A. Armstrong, M. L. Marcus, et al. 1990. Effects of atherosclerosis on the coronary microcirculation. Am. J. Physiol. 258:H529–H539.
10. Dart, A. M., and J. P. Chin-Dusting. 1999. Lipids and the endothelium. Cardiovasc. Res. 43:308–322.
11. Davignon, J., and P. Ganz. 2004. Role of endothelial dysfunction in atherosclerosis. Circulation 109:III27–III32.
12. Gawaz, M., F. J. Neumann, I. Ott, A. Schiessler, and A. Schomig. 1996. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93:229–237.
13. Golino, P., F. Piscione, J. T. Willerson, M. Cappelli-Bigazzi, A. Focaccio, B. Villari, et al. 1991. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med. 324:641–648.
14. Gremmel, T., M. Muller, S. Steiner, D. Seidinger, R. Koppensteiner, C. W. Kopp, et al. 2013a. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol. Dial. Transplant. 28:2116–2122.
15. Gremmel, T., S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C. W. Kopp. 2013b. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Transl. Res. 161:421–429.
16. Heusch, G., P. Kleinbongard, D. Bose, B. Levkau, M. Haude, R. Schulz, et al. 2009. Coronary microembolization: from bedside to bench and back to bedside. Circulation 120:1822–1836.
17. Horn, P., T. Baars, P. Kahlert, C. Heiss, R. Westenfeld, M. Kelm, et al. 2015. Release of intracoronary microparticles during stent implantation into stable atherosclerotic lesions under protection with an aspiration device. PLoS ONE 10:e0124904.
18. Kleinbongard, P., D. Boese, T. Baars, S. Moehlenkamp, T. Konorza, S. Schoener, et al. 2011a. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ. Res. 108:344–352.
19. Kleinbongard, P., D. Boese, T. Konorza, F. Steinhilber, S. Moehlenkamp, H. Eggebrecht, et al. 2011b. Acute vasomotor paralysis and potential downstream effects of paclitaxel from stents implanted for saphenous vein aorto-coronary bypass stenosis. Basic Res. Cardiol. 106:681–689.
20. Kleinbongard, P., T. Konorza, D. Boese, T. Baars, M. Haude, R. Erbel, et al. 2012. Lessons from human coronary aspirate. J. Mol. Cell. Cardiol. 52:890–896.
21. Kleinbongard, P., T. Baars, S. Mohlenkamp, P. Kahlert, R. Erbel, and G. Heusch. 2013a. Aspirate from human stented native coronary arteries vs. saphenous vein grafts: more endothelin but less particulate debris. Am. J. Physiol. Heart Circ. Physiol. 305:H1222–H1229.
22. Kleinbongard, P., A. Schleiger, and G. Heusch. 2013b. Characterization of vasomotor responses in different vascular territories of C57BL/6J mice. Exp. Biol. Med. (Maywood) 238:1180–1191.
23. Laer, S., F. Remmers, H. Scholz, B. Stein, F. U. Muller, and J. Neumann. 1998. Receptor mechanisms involved in the 5-HT-induced inotropic action in the rat isolated atrium. Br. J. Pharmacol. 123:1182–1188.
24. Lamping, K. G., H. Kanatsuka, C. L. Eastham, W. M. Chilian, and M. L. Marcus. 1989. Nonuniform vasomotor responses of the coronary microcirculation to serotonin and vasopressin. Circ. Res. 65:343–351.
25. Langlois, M., B. Bremont, D. Rousselle, and F. Gaudy. 1993. Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors. Eur. J. Pharmacol. 244:77–87.
26. Leborgne, L., E. Cheneau, A. Pichard, A. Ajani, R. Pakala, H. Yazdi, et al. 2003. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. Am. Heart J. 146:501–506.
27. Lee, M. S., S. J. Park, D. E. Kandzari, A. J. Kirtane, W. F. Fearon, E. S. Brilakis, et al. 2011. Saphenous vein graft intervention. JACC Cardiovasc. Interv. 4:831–843.
28. Leineweber, K., D. Bose, M. Vogelsang, M. Haude, R. Erbel, and G. Heusch. 2006. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J. Am. Coll. Cardiol. 47:981–986.
29. Leosco, D., M. Fineschi, C. Pierli, A. Fiaschi, N. Ferrara, S. Bianco, et al. 1999. Intracoronary serotonin release after high-pressure coronary stenting. Am. J. Cardiol. 84:1317–1322.
30. Libby, P. 2012. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32:2045–2051.
31. Ludmer, P. L., A. P. Selwyn, T. L. Shook, R. R. Wayne, G. H. Mudge, R. W. Alexander, et al. 1986. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315:1046–1051.
32. Mankad, P. S., A. H. Chester, and M. H. Yacoub. 1991. 5-Hydroxytryptamine mediates endothelium dependent coronary vasodilatation in the isolated rat heart by the release of nitric oxide. Cardiovasc. Res. 25:244–248.
33. Martin, G. R. 1994. Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol. Ther. 62:283–324.
34. Marwood, J. F. 1994. Influence of alpha 1-adrenoceptor antagonism of ketanserin on the nature of its 5-HT2 receptor antagonism. Clin. Exp. Pharmacol. Physiol. 21:955–961.
35. Muller, O., M. Hamilos, J. Bartunek, H. Ulrichts, F. Mangiacapra, J. B. Holz, et al. 2010. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. Am. J. Cardiol. 105:333–338.
36. Mulvany, M. J., and W. Halpern. 1977. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res. 41:19–26.
37. The TIMI Study Group. 1989. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N. Engl. J. Med. 320:618–627.
38. Thygesen, K., J. S. Alpert, A. S. Jaffe, M. L. Simoons, B. R. Chaitman, and H. D. White; Joint ESC/ACCF/AHA/WHF Task Force for UNiversal Definition of Myocardial Infarction. 2012. Third universal definition of myocardial infarction. J. Am. Coll. Cardiol. 60:1581–1598.
39. Vanhoutte, P. M., H. Shimokawa, E. H. Tang, and M. Feletou. 2009. Endothelial dysfunction and vascular disease. Acta Physiol. (Oxf) 196:193–222.